An international team of scientists and pharmaceutical collaborators has made a breakthrough “bench to bedside” discovery, ten years in the making, which they hope will advance the future treatment of Alzheimer’s disease in patients.
The research—conducted at the University of Glasgow and the biotechnology company Sosei-Heptares Ltd and published in Cell—describes, for the first time, the process of designing a new molecule to selectively target a specific receptor protein in the brain and demonstrating, through laboratory preclinical and human clinical studies, the potential of this approach to create superior new drugs to improve…
